Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16530690 | 1.00 | SCN9A (1.00) | SCN9A | |
| SCHEMBL16531049 | 0.93 | SCN9A (1.00) | SCN9A | |
| SCHEMBL16530691 | 0.92 | SCN9A (1.00) | SCN9A | |
| SCHEMBL16531246 | 0.92 | SCN9A (1.00) | SCN9A | |
| SCHEMBL1690656 | 0.92 | SCN9A (0.84) | SCN9A | |
| SCHEMBL16530575 | 0.91 | SCN9A (1.00) | SCN9A | |
| SCHEMBL16531006 | 0.91 | SCN9A (1.00) | SCN9A | |
| SCHEMBL16530820 | 0.90 | SCN9A (1.00) | SCN9A | |
| SCHEMBL16531649 | 0.90 | SCN9A (1.00) | SCN9A | |
| SCHEMBL322806 | 0.90 | SCN9A (1.00) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025106656-A1 | METHODS OF PREVENTING OR REDUCING CARTILAGE LOSS AND/OR JOINT DAMAGE USING NAV 1.7 INHIBITORS | YALE UNIVERSITY (US) | 2025-05-22 | — | — | WO | claimed |
| US-12533309-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-12527729-B2 | Minoxidil adjuvant therapies | CARING BRANDS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250360128-A1 | MINOXIDIL ADJUVANT THERAPIES | JUPITER WELLNESS INC (US) | 2025-11-27 | — | — | US | disclosed |
| WO-2025106656-A1 | METHODS OF PREVENTING OR REDUCING CARTILAGE LOSS AND/OR JOINT DAMAGE USING NAV 1.7 INHIBITORS | YALE UNIVERSITY (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4536354-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20240009101-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2024-01-11 | — | — | US | disclosed |
| US-20230404886-A1 | MINOXIDIL ADJUVANT THERAPIES | Jupiter Wellness, Inc. (US) | 2023-12-21 | — | — | US | disclosed |
| CN-117243839-A | Minoxidil adjuvant therapy | 应用生物学股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-11766392-B2 | Minoxidil adjuvant therapies | Jupiter Wellness, Inc. (US) | 2023-09-26 | — | — | US | disclosed |
| CN-110088093-B | Acyl sulfonamide nav1.7 inhibitors | 百时美施贵宝公司 | 2023-06-13 | — | — | CN | disclosed |
| US-11628132-B2 | Minoxidil adjuvant therapies | Jupiter Wellness, Inc. (US) | 2023-04-18 | — | — | US | disclosed |
| US-20220296486-A1 | Minoxidil Adjuvant Therapies | Jupiter Wellness, Inc. | 2022-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527729-B2 | Minoxidil adjuvant therapies | RXRA, RXRB, RXRG | SCN9A 1256/4885 |
| US-12533309-B2 | Minoxidil adjuvant therapies | RXRG, RXRA, RXRB | SCN9A 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.